Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

5-HT3 receptor antagonists: differences and similarities

F Roila1, E Ballatori, M Tonato

  • 1Medical Oncology Division, Policlinico Hospital, Perugia, Italy.

European Journal of Cancer (Oxford, England : 1990)
|August 1, 1997
PubMed
Summary

Pharmacological differences between 5-HT3 receptor antagonists do not impact clinical efficacy or safety for preventing cisplatin-induced emesis. Economic factors, such as dosage, are the primary differentiators.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2021
Same author

Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

MASCC/ESMO Antiemetic Guidelines: Introduction to the 2016 guideline update.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2016
Same author

A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients.

Critical reviews in oncology/hematology·2015

Area of Science:

  • Pharmacology
  • Oncology
  • Clinical Medicine

Background:

  • Pharmacological studies show variations in 5-HT3 receptor antagonist properties like binding, potency, and duration.
  • The clinical implications of these pharmacological differences on efficacy and safety are not fully understood.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of different 5-HT3 receptor antagonists.
  • To determine if pharmacological differences translate to clinical practice.
  • To assess the use of these agents in preventing chemotherapy-induced emesis.

Main Methods:

  • A comprehensive literature review of 22 comparative studies on 5-HT3 receptor antagonists.
  • Focus on seven large, double-blind clinical trials for cisplatin-induced emesis.

Related Experiment Videos

  • Analysis of available data for moderately emetogenic chemotherapy-induced emesis.

    • Main Results:

    • Seven large trials indicate that ondansetron, granisetron, tropisetron, and dolasetron have nearly identical antiemetic activity and tolerability for cisplatin-induced emesis.
    • No significant differences in efficacy or safety were found among these agents in this context.
    • Economic differences are linked to administration costs and schedules.
    • Limited data exists for preventing emesis from moderately emetogenic chemotherapy, with conflicting results.

    Conclusions:

    • For preventing cisplatin-induced emesis, no single 5-HT3 receptor antagonist offers superior efficacy or safety.
    • Cost-effectiveness may vary based on dosage and administration.
    • Further research is needed to clarify the role of these antagonists in preventing emesis from moderately emetogenic chemotherapy.